Form 4: Sutro Biopharma Director Joseph Lobacki Granted 50,000 Stock Options

Sutro Biopharma, Inc. Director Joseph M. Lobacki was granted 50,000 stock options with an exercise price of $0.85, vesting monthly and fully by June 2026.

Summary

• Joseph M. Lobacki, a Director of Sutro Biopharma, Inc. (STRO), was granted 50,000 stock options on June 6, 2025.
• The options have an exercise price of $0.85 per share and are set to expire on June 6, 2035.
• Vesting for these options will commence on July 6, 2025, with 8.33% of the total shares vesting monthly.
• Full vesting (100%) is scheduled to occur on the earlier of the issuer's 2026 annual stockholders meeting or June 6, 2026, contingent upon Mr. Lobacki's continued service to the company.
• Following this transaction, Mr. Lobacki beneficially owns 50,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a standard compensation practice that aligns management interests with shareholders. It is not a significant event that would drastically alter the company's financial outlook but is generally viewed as a positive for corporate governance and incentive alignment.

Positives

• The grant of 50,000 stock options to Director Joseph M. Lobacki aligns his interests with those of shareholders, incentivizing long-term performance and value creation.
• The exercise price of $0.85 per share is relatively low, suggesting a strong potential for future value if the company's stock price appreciates.

Risks

• The vesting of the options is contingent on the reporting person's continued provision of service to the issuer; if service ceases before full vesting, unvested options may be forfeited.
• The ultimate value of the stock options is dependent on the future market price of Sutro Biopharma's common stock, which is subject to market volatility and company performance.

Future Outlook

The grant of stock options with a vesting schedule extending to June 2026 indicates an expectation of continued service from Director Joseph M. Lobacki and aligns his future compensation with the company's long-term performance and shareholder value creation.

Industry Context

Granting stock options to directors and executives is a common practice in the biotechnology and pharmaceutical industries, serving as a key component of compensation packages designed to attract, retain, and incentivize leadership by aligning their financial interests with shareholder value creation.

Comparison to Industry Standards

• The practice of granting stock options to directors is a standard compensation mechanism across publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• While specific grant sizes and exercise prices vary widely based on company size, stage, and individual roles, a grant of 50,000 options to a director is within the typical range for a company of Sutro Biopharma's profile, aiming to provide long-term incentives.
• No specific comparable companies, projects, or results are mentioned in the document to provide a direct comparison.

Corporate Governance

Related Party Transactions

• The grant of 50,000 stock options to Joseph M. Lobacki, a Director of Sutro Biopharma, Inc., constitutes a related party transaction as it involves a transaction between the company and a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, potentially leading to better long-term performance and strategic decisions.
• Employees: No direct impact on general employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• The granted stock options will begin their monthly vesting schedule on July 6, 2025.
• The options will continue to vest until fully vested on the earlier of the issuer's 2026 annual stockholders meeting or June 6, 2026, subject to continued service.

Key Dates

Keywords

Sutro Biopharma, STRO, Joseph Lobacki, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Biopharma, Vesting